AKT1 and non-small cell lung carcinoma: Because mutant EGFR potently stimulates the AKT pathway [7], we anticipated that a similar mechanism of BIM induction would be activated after gefitinib treatment of NSCLC cells expressing hyperactive mutant EGFR.